CellChorus
CellChorus, founded by Navin Varadarajan, PhD, is a biotechnology company specializing in dynamic single-cell analysis.
Profile
CellChorus develops AI-driven platforms to analyze the behavior of individual immune cells over time.
CellChorus, founded by Navin Varadarajan, PhD, is a biotechnology company specializing in dynamic single-cell analysis. The company’s flagship platform, TIMING™ (Time-lapse Imaging Microscopy in Nanowell Grids), uses artificial intelligence to evaluate the spatiotemporal performance of thousands of immune cells simultaneously. This technology allows researchers to understand how individual cells move, activate, interact, kill, and survive, providing insights that are critical for advancing cell therapies, antibodies, and vaccines.
CellChorus has secured significant funding, including a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) awarded in May 2026. The company collaborates with leading institutions like Stanford Medicine to develop functional assays predicting CAR-T response in lymphoma patients. CellChorus’s technology has been validated in numerous peer-reviewed publications, including studies in Nature Immunology and Science Advances. The company’s focus on high-throughput, single-cell analysis positions it uniquely in the biotech landscape, offering tools that bridge functional profiling with multi-omic data integration.
Who buys this
- Biotechnology companies developing cell therapies
- Pharmaceutical companies researching antibodies
- Academic institutions studying immunology
- Clinical research organizations (CROs)
- Vaccine developers
Strengths and what to watch
Strengths
- Proprietary TIMING™ platform enables high-throughput, single-cell analysis
- Strong validation through peer-reviewed publications in top-tier journals
- Collaborations with leading institutions like Stanford Medicine
Watch for
- High competition in the single-cell analysis market
- Dependence on continued NIH and SBIR funding
- Scalability challenges in processing large datasets
Recent moves
Key Information
- Founded
- 2017
- Headquarters
- Houston, Texas
Frequently Asked Questions
What is CellChorus and what does it do?
CellChorus is a biotech company developing AI platforms to analyze immune cell behavior. Its TIMING™ technology uses time-lapse microscopy and AI to track thousands of individual cells simultaneously, helping researchers study cell movement, activation, and interactions for therapy development. (42 words)
How does CellChorus' TIMING platform work?
The TIMING™ platform combines nanowell grids with AI-powered time-lapse imaging. It captures and analyzes spatiotemporal data from thousands of single cells in parallel, enabling researchers to quantify cell behaviors like killing efficiency and survival rates over time. (42 words)
What are the medical applications of CellChorus technology?
CellChorus' platform aids in developing cell therapies, antibodies, and vaccines. Its 2026 NCI-funded collaboration with Stanford Medicine focuses on predicting CAR-T cell response in lymphoma patients, demonstrating clinical potential for immunotherapy optimization. (42 words)
Is CellChorus' technology scientifically validated?
Yes, CellChorus' methods have been published in top journals like Nature Immunology and Science Advances. Their TIMING™ platform's ability to profile single-cell function is peer-reviewed, with studies demonstrating applications in immune cell analysis. (43 words)
Who uses CellChorus' single-cell analysis platform?
Biotech firms, pharma researchers, academic institutions, and CROs utilize CellChorus. Customers include cell therapy developers and vaccine researchers needing high-throughput functional analysis of immune cells at single-cell resolution. (40 words)
What funding has CellChorus received recently?
In May 2026, CellChorus secured a Phase I SBIR grant from the National Cancer Institute. This funds their collaboration with Stanford Medicine to develop AI-driven assays for predicting CAR-T cell therapy responses. (42 words)
Sources
- cellchorus.com — Publications validating TIMING™ platform
- cellchorus.com — NCI SBIR grant awarded in May 2026
- cellchorus.com — Description of TIMING™ platform capabilities
- cellchorus.com — Recent news and updates on CellChorus